Leiden, The Netherlands and Seattle, WA, January 5, 2012 - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its U.S. multicenter Phase II clinical trial with Fibrocaps in spinal, peripheral vascular and general...

Leiden, The Netherlands and Seattle, WA, November 15, 2011 - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its multicenter Phase II clinical trial with Fibrocaps in liver resection surgery resulted...

Leiden, The Netherlands and Seattle, WA, September 14, 2011 - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has completed patient enrollment in its two (U.S. and Dutch) prospective, randomized, controlled, multi-center...

Leiden, The Netherlands and Seattle, WA, May 3, 2011 - ProFibrix B.V., a leader in the development of innovative products that help stop bleeding (hemostasis) after surgery, today announced the successful closing of a series B follow-on financing. In conjunction...

Leiden, The Netherlands and Seattle, WA, March 8, 2011 - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has initiated a prospective, multi-center Phase II study with its lead product Fibrocaps...

Leiden and Rotterdam, The Netherlands, August 23, 2010 - ProFibrix B.V., a leader in the development of innovative products based on the blood clotting protein fibrinogen today presents the first Phase II data for its lead product Fibrocaps™. Fibrocaps is...

Leiden, The Netherlands and Seattle, WA, June 17, 2010 - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced that it has entered into an agreement with CSL Behring for the clinical...

Leiden, The Netherlands and Seattle, WA, March 11, 2010 - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the conclusion of the first Phase II trial testing its unique new hemostat...

Leiden, The Netherlands and Seattle, WA, August 24, 2009 - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment.  The financing...

Leiden, The Netherlands and Seattle, WA, January 7, 2010 - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced that SenterNovem, an agency of the Dutch Ministry of Economic Affairs, has granted...

Leiden, The Netherlands, January 13 2009 - ProFibrix B.V., today announced that it has concluded a commercial license agreement with Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) for PER.C6®,...

Leiden, The Netherlands, September 17 2008: ProFibrix B.V., a Dutch biotech company focused on products to stop bleeding and initiate tissue repair, today announced that it has added Jan Ohrstrom,...

Leiden, The Netherlands, 26 March 2007. ProFibrix  B.V., a Dutch biotech company focused on products to stop bleeding and initiate tissue repair,  today announced that it has closed a Series A financing raising $ 11 Million . The round was...